阿帕替尼联合紫杉醇治疗晚期化疗耐药HER―2阴性胃癌临床效果评价.docVIP

阿帕替尼联合紫杉醇治疗晚期化疗耐药HER―2阴性胃癌临床效果评价 　　[摘要] 目的 探索阿帕替尼治疗晚期一线化疗耐药HER-2阴性胃癌的临床效果。方法 方便选取2015年9月―2016年9月期间该院晚期一线化疗耐药HER-2阴性胃癌100例患者，抽签化分组，即每组50例，对照组和观察组分别采用紫杉醇联合顺铂化疗和紫杉醇化疗联合阿帕替尼治疗。结果 观察组患者主要不良反应为乏力、高血压，对照组患者主要不良反应为消化道反应、白细胞下降；两组患者治疗有效率差异无统计学意义，但胃粘膜组织中性粒细胞浸润程度（0.12±0.37）、单核细胞浸润程度（0.63±0.29）、KPS评分（83.47±5.41）分、中位PFS（9.63±0.52）月均优于对照组（P0.05）。结论 对晚期一线化疗耐药HER-2阴性胃癌患者实施紫杉醇单药联合阿帕替尼治疗效果显著，不良反应可耐受，并显著延长患者中位PFS。 　　[关键词] 阿帕替尼；晚期化疗；耐药胃癌；效果 　　[中图分类号] R735 [文献标识码] A [文章编号] 1674-0742（2017）12（b）-0127-03 　　[Abstract] Objective To explore the clinical effect of apatinib and paclitaxel in treatment of advanced chemotherapy drug-tolerance HER-2 negative gastric cancer. Methods 100 cases of patients with advanced first-line chemotherapy drug-tolerance HER-2 negative gastric cancer in our hospital from September， 2015 to September， 2016 were convenient selected and divided into two groups with 50 cases in each， the control group were treated with paclitaxel combined with cisplatin chemotherapy， while the observation group were treated with paclitaxel chemotherapy combined with apatinib. Results The major adverse reactions in the observation group were weak and hypertension， while the major adverse reactions in the control group were gastrointestinal reaction and neutropenia， and the difference in the treatment effective rate between the two groups was not obvious， but the neutrophil infiltration of orthotopic implanted tumor， monocyte infiltration， KPS score and median PFS were respectively （0.12±0.37）， （0.63±0.29）， （83.47±5.41）points and （9.63±0.52）months， which were better than those in the control group（P0.05）. Conclusion The effect of single paclitaxel combined with apatinib in patients with advanced chemotherapy drug-tolerance HER-2 negative gastric cancer is obvious， and the adverse reactions are tolerated， which can obviously prolong the median PFS. 　　[Key words] Apatinib； Advanced chemotherapy； Drug-resistant gastric cancer； Effect 　　胃癌发生率可随着人们生活方式和饮食习惯的改变而上升，具有发病率高、晚期胃癌死亡率高、疗效欠佳、